[ad_1]
An HIV vaccine was tested in approximately 400 people from different geographic locations. It has proven safe and able to activate the immune system of participants in the clinical trial. The results "represent a milestone" for the creation of a vaccine that could be licensed in the future. Despite the success of the first tests, the test manager, virologist Dan Barouch, asked to be careful in evaluating the results, as there is no guarantee that However, the data already known represent a major breakthrough in the study of a vaccine against the virus.
Up to now, the great diversity of HIV strains has been the major impediment to the success of all vaccines that have been tested in the scientific journal The Lancet, where the study has been published
More than 1.8 million new cases of infection worldwide have been diagnosed in 2016 – 160,000 in Europe – and there are still no registered prophylaxis vaccines.
Parallel studies in humans and monkeys rhesus and tests have shown that it can be used in humans from different geographical regions.
Participants were recruited from 12 clinics in East Africa, South Africa, Thailand and the United States. Healthy, non-HIV-infected participants (aged 18 to 50 years) and considered to be at low risk of infection with the human immunodeficiency virus were included.
The experimental vaccine was well tolerated and proved effective for both adult humans and monkeys Rhesus .
"These results should be interpreted with caution," says lead author of the study, Dan Barouch, quoted by El País
"The Challenges of Developing a Vaccine Against HIV is unprecedented and the ability to induce a specific immune response to HIV does not necessarily indicate that the vaccine protects humans from infection. "
The clinical trial is going to Now being extended to 2,600 women in South Africa is at risk of contracting the virus and wider results are expected by 2021 or 2022.
"We are so in need of vaccines," said Francois Venter of the University of the Witwatersrand (South Africa), but "we already know it: promising experimental vaccines that do not materialize," he added, quoted by AFP
. is probably not the definitive vaccine, but it can be a phenomenal breakthrough, "said the Jean-Dani El Lelièvre, of the Institute for Vaccine Research. "In the best case", this research will produce a vaccine that will be administered in "almost 10 years".
About 37 million people are living with HIV or AIDS, according to the World Health Organization. Portugal is one of the most prosperous countries in the fight against HIV
Portugal is part of the small group of European countries with more HIV-positive people and (19659002) In an interview with the agency Lusa, Masoud Dara, coordinator of the WHO Communicable Diseases Program, welcomed the results of the study,
"Portugal has taken an exemplary course in prevention, detection, treatment and caring for HIV-infected patients, "said Masoud Dara, pointing out that and the country has achieved almost all the goals set out in the UN's HIV / AIDS program – UNAIDS, known as 90 / 90/90.
The program aims to ensure that, by 2020, 90% of people living with HIV / AIDS 90% of those diagnosed are in treatment and 90% of those treated achieve an undetectable viral load to the point that 39, it is impossible to transmit the infection.
Portugal has already achieved one of these goals – the identification of infected people – and has managed to get 89% of patients in treatment to achieve a very undetectable burden, added the secretary of State of Health, Fernando Araújo.
"Copy" is the adjective chosen by Masoud Dara, who places Portugal, with countries like Denmark, Iceland, Sweden, Great Britain and Northern Ireland, who have already achieved the goal of 90-90-90
. 53 European countries participating in the program show a worrying situation: only 69% of patients are identified, the majority are not in treatment (58%) and only 36% of treated patients are no longer a threat in the transmission of the virus, according to data
Masoud Dara points out that the situation in the countries of Eastern Europe is the main reason for these low percentages, since in this region of the world AIDS remains a taboo subject. "In 2016, there were 160,000 new infections in Europe, of which 80% in the eastern countries" he lamented, explaining that in the region the number of new patients continues to 39, increase, partly for lack of prevention and limited access
Outcome: In the East, only 63% of patients are diagnosed, only one in four (28%) is on treatment and 88% patients undergoing treatment remain a danger in terms of viral transmission.
[ad_2]
Source link
